Can remicade cause lupus like syndrome?

Can Remicade trigger lupus-like syndrome?
Remicade (infliximab) is a TNF inhibitor used for inflammatory conditions. It can induce lupus-like syndrome, a known side effect of this drug class. Symptoms usually involve joint pain, rash, fatigue, and sometimes low blood-cell counts or positive ANA and anti-dsDNA antibodies. Most cases resolve after stopping the drug.

Why do TNF inhibitors trigger lupus-like symptoms?
TNF normally suppresses autoantibody production; blocking it can allow these antibodies to rise. In clinical studies, up to 50 percent of Remicade patients developed positive ANA, but only a small fraction developed full lupus-like illness. The syndrome appears more often in patients treated for longer periods or at higher doses.

What should patients watch for?
New or worsening joint pain, unexplained fever, skin rashes (especially butterfly rash on the face), chest pain, or shortness of breath warrant prompt medical review. Blood tests for ANA, anti-dsDNA, and complement levels help confirm whether symptoms relate to drug-induced lupus.

How common is it and when does it start?
Drug-induced lupus from TNF inhibitors occurs in roughly 0.5–1 percent of users. Onset can range from weeks to several years after starting therapy. Women and patients with rheumatoid arthritis or Crohn’s disease appear at higher risk, though exact rates vary by study.

Does stopping Remicade reverse the syndrome?
Symptoms and autoantibodies typically improve within weeks to months after discontinuation. In some cases, short courses of corticosteroids speed recovery. Switching to a different biologic that does not block TNF may be considered if ongoing treatment is still needed.

Can patients stay on Remicade if lupus symptoms appear?
Continued use is usually avoided once drug-induced lupus is diagnosed. Re-challenge with the same drug has led to recurrence in reported cases. Physicians generally move to alternative agents such as vedolizumab or ustekinumab when feasible.

How does Remicade’s risk compare with other TNF inhibitors?
All TNF blockers carry some risk of lupus-like syndrome, but rates differ slightly. Adalimumab and etanercept show similar incidence; certolizumab and golimumab have fewer published reports. The overall class effect is considered comparable.

Are biosimilars likely to carry the same risk?
Biosimilar infliximab products share the same active molecule, so lupus-like syndrome remains possible. Post-marketing data have not shown meaningful differences in autoimmune side effects between originator Remicade and approved biosimilars.

When does Remicade’s patent protection end?
Remicade’s composition-of-matter patent expired in the United States in 2013, opening the door to biosimilars. Several infliximab biosimilars are already marketed, though additional manufacturing or dosing patents may still affect specific formulations.